

e-Table 1. Drug classification

Category Name	Generic Name
Antiplatelets	clopidogrel, cilostazol, ticlopidine ² , beraprost, beraprost–long acting, complavin
Anticoagulants ^{2,3}	dabigatran
Statins ^{1,2,3}	atorvastatin ² , simvastatin, pitavastatin, fluvastatin, pravastatin, rosuvastatin, amlodipine/atorvastatin
Sodium channel blockers ^{4,5†}	mexiletine, aprindine, cibenzoline
Beta blocker	acebutolol ²
Class III antiarrhythmic drugs	amiodarone ^{1–6}
Calcium channel blockers	bepridil ¹ , amlodipine/atorvastatin, telmisartan/amlodipine, valsartan/amlodipine, valsartan/cilnidipine, candesartan/amlodipine
Angiotensin/convertng enzyme inhibitor ^{2‡}	enalapril
Thiazides	trichlormethiazide, hydrochlorothiazide ^{3,5} , benzyhydrochlorothiazide/reserpine/carbazochrome, mefruside, telmisartan/hydrochlorothiazide, valsartan/hydrochlorothiazide, candesartan/hydrochlorothiazide, candesartan/trichlormethiazide, losartan/hydrochlorothiazide
NSAIDs	diclofenac ² , celecoxib, loxoprofen, etodolac, nabumetone, pranoprofen
Anti-rheumatics	actarit, iguratimod, tofacitinib, penicillamine ^{2–5} , leflunomide ^{1,3} , sodium aurothiomalate ^{2–6#} , bucillamine
Leukotriene receptor antagonist ^{2*}	pranlukast
5-ASA	mesalazine, salazosulfapyridine ⁵
Tricyclic antidepressant	Imipramine ⁵ , cromipramine, maprotiline
Antiepileptics	valproate, phenytoin ^{2,3,5} , ethotoin, carbamazepine ^{2–5} , zonisamide
Interferon ^{1,2,3}	interferon/alpha/2b, interferon/alpha, interferon/beta/1a, interferon/beta, interferon/gamma/1a, PEG/interferon/alpha/2a, PEG/interferon/alpha/2b
Immunoglobulin ⁶	thymoglobuline, zetbulin
Sulfamethoxazole/trimethoprim	sulfamethoxazole/trimethoprim ²
Quinolones	levofloxacin, garenoxacin, moxifloxacin, pazufloxacin, tosufloxacin, sitafloxacin, ofloxacin, ciprofloxacin ² , norfloxacin, prulifloxacin, lomefloxacin
Tetracyclines	minocycline ^{2,3}
Beta-lactams	penicillin ^{2,5} (augmentin, amoxicillin, sultamicillin, piperacillin/tazobactam, piperacillin); cephalosporin ² (cefoperazone/sulbactam, cefaclor, cefazolin, cefalexin, cefalotin, cefixime, cefepime, ceftazopran, cefotaxime, cefotiam, cefoperazone, cefcapene, cefditoren, cefdinir, ceftazidime, ceftizoxime, ceftibuten, ceftoram, ceftriaxone, cefpirome, cefpodoxime, cefminox, cefmetazole, cefmenoxime, cefroxadine, cefuroxime, flomoxef, latamoxef); penem (imipenem/cilastatin, tebipenem, doripenem, panipenem/betamipron, biapenem, faropenem, meropenem)
Anti-tuberculosis drugs	streptomycin, rifampicin ² , isonicotinyl hydrazide methanesulfonate, isoniazid ^{2,3,5} , ethambutol
EGFR inhibitors	afatinib, erlotinib ^{1,3} , gefitinib ^{1–3,6}
Molecular targeted drugs	imatinib ^{1,3} , sunitinib ⁶ , sorafenib, vandetanib, pazopanib, bortezomib, lapatinib
Anti PD-1 antibody	nivolumab ¹
Anti CTLA4 antibody	ipilimumab ¹
mTOR inhibitor ¹	everolimus

Platinum	oxaliplatin ⁶ , carboplatin ⁶ , cisplatin ⁶ , nedaplatin, mliplatin
Topoisomerases	irinotecan ^{1,6} , nogitecan, etoposide ^{3,6} , sobuzoxane
Pyrimidine	capecitabine, gemcitabine ^{1-3,6} , cytarabine ocfosfate, cytarabine ^{2,3,6} , tegafur/gimeracil/oteracil, 5-fluorouracil ^{4,6} , trifluridine, doxifluridine
Anthracyclines	amrubicin, epirubicin, adriamycin ⁴ , doxorubicin ^{2,3,6} , pirarubicin, mitoxantrone
Biological products	infliximab ^{2,3,6} , adalimumab ^{2,3} , abatacept, ustekinumab, etanercept, golimumab, certolizumab, ofatumumab, gemtuzumab, trastuzumab ³ , trastuzumab emtansine, panitumumab ¹ , bevacizumab ³ , mogamulizumab, rituximab ^{1,3,6} , tocilizumab ¹
Microtubule polymerisation inhibitors	eribulin, vinblastine ^{2-4,6} , docetaxel ^{1,3,6} , nab-paclitaxel, paclitaxel ^{2,3,6} , vinorelbine ⁶ , vindesine ^{4,6}
Purine metabolism antagonists	azathioprine ^{3,4,6} , mizoribine, cladribine, fludarabine ^{3,6}
Folic acid antagonists	methotrexate ¹⁻⁶ , pemetrexed ¹
DNA synthesis inhibitors	bleomycin ¹⁻⁶ , peplomycin, mitomycin ^{2-4,6}
Hormone therapy drugs	goserelin, degarelix, leuprorelin ⁶ , danazol, bicalutamide, flutamide ³ , anastrozole, tamoxifen
Alkylators	ifosfamide, cyclophosphamide ^{1-4,6} , temozolomide, nimustine, busulfan ^{3,4,6} , procarbazine ^{3,4,5} , bendamustine, melphalan ^{3,4,6} , ranimustine
Cytokine ^{6**}	celmoleukin
Thalidomide	thalidomide ³
Retinoid	tretinoin ^{2,6}
BCG ³	immucyst

NSAIDs: non-steroidal anti-inflammatory drugs; 5-ASA: 5-aminosalicylic acid; G-CSF: granulocyte-colony stimulating factor; EGFR: epidermal growth factor receptor; ALK: anaplastic lymphoma kinase; PD-1: programmed cell death 1; CTLA4: cytotoxic T-lymphocyte-associated antigen 4; DNA: deoxyribonucleic acid; BCG: Bacille Calmette Guerin

†, referred to lidocaine; ‡, referred to captopril; #, referred to as gold or gold salts; *, referred to zafirleukast; **, referred to IL-2 and Tumor necrosis factor

1. Skeoch S, Weatherley N, Swift AJ, Oldroyd A, Johns C, Hayton C, et al. Drug-Induced Interstitial Lung Disease: A Systematic Review. *J Clin Med*. 2018; 7. doi: 10.3390/jcm7100356.
2. Prasad R, Gupta P, Singh A, Goel N. Drug induced pulmonary parenchymal disease. *Drug Discov Ther*. 2014;8(6):232-7.
3. Schwaiblmair M, Behr W, Haeckel T, Markl B, Foerg W, Berghaus T. Drug induced interstitial lung disease. *Open Respir Med J* 2012; 6: 63-74.
4. Cooper JA, Jr., White DA, Matthay RA. Drug-induced pulmonary disease. Part 1: Cytotoxic drugs. *Am Rev Respir Dis*. 1986; 133: 321-40.
5. Cooper JA, Jr., White DA, Matthay RA. Drug-induced pulmonary disease. Part 2: Noncytotoxic drugs. *Am Rev Respir Dis*. 1986; 133: 488-505.
6. Dhokarh R, Li G, Schmickl CN, Kashyap R, Assudani J, Limper AH, Gajic O. Drug-associated acute lung injury: a population-based cohort study. *Chest* 2012; 142: 845-850.

e-Tables 2. Population of patients prescribed drugs with potential risk during hospitalisation

Drug category with potential risk	Prescribed during hospitalisation				Prescribed before corticosteroids during hospitalisation			
	Cases		Controls		Cases		Controls	
	(n = 1,541)		(n = 5,677)		(n = 1,541)		(n = 5,677)	
	n	%	n	%	n	%	n	%
Antiplatelets	111	7.2	353	6.2	44	2.9	150	2.6
Anticoagulants	14	0.9	34	0.6	7	0.5	11	0.2
Statins	200	13	763	13	60	3.9	294	5.2
Sodium channel blockers	27	1.8	67	1.2	10	0.6	30	0.5
Beta blocker	0	0	1	0.01	0	0	1	0.02
Class III antiarrhythmic drugs	70	4.5	72	1.3	45	2.9	36	0.6
Calcium channel blockers	19	1.2	49	0.9	5	0.3	17	0.3
Angiotensin/converting enzyme inhibitor	46	3.0	173	3.0	16	1.0	73	1.3
Thiazides	43	2.8	159	2.8	11	0.7	67	1.2
NSAIDs	791	51	2159	38	360	23	952	17
Anti-rheumatics	5	0.3	27	0.5	1	0.06	6	0.1
Leukotriene receptor antagonist	5	0.3	33	0.6	0	0	6	0.1
5-ASA	20	1.2	47	0.8	3	0.2	10	0.2
Tricyclic antidepressant	5	0.3	16	0.3	1	0.06	8	0.1
Antiepileptics	42	2.7	170	3.0	16	1.0	53	0.9
Interferon	2	0.1	12	0.2	2	0.1	8	0.1
Immunoglobulin	1	0.1	1	0.02	0	0	0	0
Sulfamethoxazole/trimethoprim	921	60	433	7.6	30	1.9	47	0.8
Quinolones	662	43	1106	19	175	11	246	4.3
Tetracyclines	117	7.6	167	2.9	41	2.7	71	1.3
Beta-lactams	1274	83	3460	61	639	41	1942	34
Anti-tuberculosis drugs	53	3.4	67	1.2	14	0.9	28	0.5
EGFR inhibitors	109	7.1	226	4.0	76	4.9	109	1.9
Molecular targeted drugs	23	1.5	55	1.0	3	0.2	7	0.1
Anti PD-1 antibody	1	0.06	2	0.03	1	0.06	1	0.02
Anti CTLA4 antibody	0	0	0	0	0	0	0	0
mTOR inhibitor	3	0.2	7	0.1	2	0.1	5	0.09
Platinum	114	7.4	663	12	4	0.3	11	0.2
Topoisomerases	51	3.3	221	3.9	3	0.2	5	0.09
Pyrimidine	121	7.9	338	6.0	16	1.0	54	1.0
Anthracyclines	51	3.3	132	2.3	9	0.6	12	0.2
Biological products	45	2.9	198	3.5	3	0.2	5	
Microtubule polymerisation inhibitors	147	9.5	378	6.7	4	0.3	11	0.09
Purine metabolism antagonists	6	0.4	21	0.4	0	0	2	0.04
Folic acid antagonists	59	3.8	249	4.4	3	0.2	4	0.07
DNA synthesis inhibitors	4	0.3	5	0.09	1	0.06	3	0.05
Hormone therapy drugs	18	1.2	34	0.6	8	0.5	10	0.17
Alkylators	69	4.5	118	2.1	0	0	4	0.07
Cytokine	0	0	0	0	0	0	0	0
Thalidomide	1	0.06	5	0.09	0	0	1	0.02
Retinoid	0	0	2	0.04	0	0	0	0

BCG	1	0.06	0	0	0	0	0	0
-----	---	------	---	---	---	---	---	---

NSAIDs: non-steroidal anti-inflammatory drugs; 5-ASA: 5-aminosalicylic acid; EGFR: epidermal growth factor receptor; PD-1: programmed cell death 1; CTLA4: cytotoxic T-lymphocyte-associated antigen 4; DNA: deoxyribonucleic acid; BCG: Bacille Calmette Guerin